Multiple fusion genes with well-established leukemia-associated fusion partners have also been described in advanced phase CML (including CBFB, RUNX1 and KMTD2), in addition to recurrent novel mutations (such as in SETD2, SETD1B, BCOR and UBE2A genes) that could have emerging roles as contributors to CML evolution [132,133]. The gene discussed is SETD2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.